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Abstract 
Flavin-containing monooxygenases (FMO) catalyze the oxidation of certain xenobiotics and drugs which contain a nucle- 
ophilic heteroatom. Here we report the first assessment of human brain flavin-containing monooxygenase from tissues obtained 
at autopsy from seven traffic accident victims. Human brain microsomes catalyzed the S-oxidation or N-oxidation of model 
substrates methimazole and N,N-dimethylaniline, r spectively. The psychoactive drugs chlorpromazine, imipramine and fluoxe- 
tine, were also metabolized by human brain FMO. 'Western' immunoblot analyses revealed immunological cross-reactivity of the 
human brain FMO with rabbit pulmonary FMO. Immunocytochemistry further revealed the localization of the FMO predomi- 
nantly in the neuronal cell bodies in the magnocellular reticular nuclei, colliculi and substantia nigra. Human brain clearly 
contains an active FMO system, and it is conceivable that such enzyme(s) are significantly involved in the local metabolism and 
modulation of pharmacological effects of psychoactive drugs. 
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Microsomal flavin-containing monooxygenases 
(FMOs) catalyze the NADPH-dependent oxidation of 
a variety of xenobiotics which contain nucleophilic het- 
eroatoms. Typically, nitrogen-, sulfur- or phosphorus- 
containing functional groups are sites for oxidation by 
the enzyme [18]. Many psychoactive drugs fall into this 
category and are substrates for hepatic and pulmonary 
flavin-containing monooxygenase (FMO). The pres- 
ence of FMO has been documented in several organs 
including liver [13], lung [17] and kidney [4]. 
Hepatic and pulmonary FMOs have been shown to 
be distinct proteins [16,17,19]. FMO-mediated oxida- 
tion of model substrate N,N-dimethylaniline has been 
demonstrated in adult and fetal human liver [8]. More 
recently, FMO-mediated N-oxidation of imipramine in 
human kidney has been reported [10]. Human hepatic 
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FMO has been cloned and sequenced [7,11]. While the 
existence of multiple forms of FMO has been known, 
recent interest has centered on the polymorphism seen 
in the N-oxygenation of trimethylamine [6] and nico- 
tine [1] in humans probably due to a genetic defect in 
one or more forms of FMO. 
Studies from our laboratory have demonstrated the 
presence of FMO in the rat brain and the enzyme's 
ability to metabolize model substrates [2] and antide- 
pressants uch as imipramine and fluoxetine [3]. To our 
knowledge the presence of FMO in human brain has 
not heretofore been demonstrated. 
Human brain tissues were obtained at autopsy from 
seven, male traffic accident victims. The average age of 
the subjects was 45.4 :~ 18.2 years, and the interval 
between death and autopsy was 6.2 + 3.3 h. None of 
the subjects had any known neurological disorders. 
Following autopsy, the meninges and blood vessels 
were removed and the brain regions (cortex, cerebel- 
lum, thalamus, striatum, hippocampus, pons, midbrain 
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Table 1 
Apparent kinetic constants, Krn and I'm=,, for flavin-containing 
monooxygenase mediated oxidation of various substrates by human 
brain microsomes 
Substrates K m Vma x
Chlorpromazine 19.5/zM 231.0 
Imipramine 22.0/zM 271.0 
Fluoxetine 16.0 # M 650.0 
Methimazole 17.1 #M 29.8 
N,N-Dimethylaniline ('low') 2.3 mM 565.0 
N,N-Dimethylaniline ('high') 1.2 #M 5.4 
The K m and Vm~ x values were determined in cortical microsomes 
obtained at autopsy (case VI, see legend to Fig. 1). Vma ~ is expressed 
as nmol of NADPH oxidized/min/mg protein. 
and medulla) were dissected out using appropriate 
anatomical landmarks. The tissues were stored at 
-70°C prior to analysis. 
Microsomes were prepared by calcium aggregation 
method as described [3]. Microsomal protein concen- 
trations were estimated by a dye-binding method [5] 
and by the method of Lowry [12]. FMO activity was 
measured using a variety of substrates, namely methi- 
mazole, N,N-dimethylaniline, imipramine, fluoxetine 
and chlorpromazine. The substrate-stimulated rate of 
NADPH oxidation was measured essentially as de- 
scribed [3]. 
Immunoblot analyses were carried out following 
sodium dodecyl sulfate polyacrylamide gel electro- 
phoresis (SDS-PAGE) [9], and transfer of protein to 
nitrocellulose membrane [15], using antibody to pig 
hepatic FMO [19] or rabbit pulmonary FMO [17]. 
Different regions from human brain were fixed in 
formalin; frozen sections (10-20 ~m) were cut on a 
cryostat. The immunocytochemical localization was 
carried out essentially as described [3] using the anti- 
body to rabbit pulmonary FMO. Control sections were 
incubated with non-immune immunoglobulin. 
The FMO-mediated oxidation of model substrates 
methimazole and N,N-dimethylaniline by microsomes 
from human brain regions is depicted in Fig. 1A. 
Significant activity was detectable in all the brain re- 
gions examined. FMO-mediated oxidation of the psy- 
choactive drugs chlorpromazine, imipramine and fluox- 
etine was also observed in human brain microsomes 
(Fig. 1B). The distribution of FMO among the various 
Fig. 1. FMO-mediated oxidation of (A) methimazole and N,N-di- 
methylaniline and (B) chlorpromazine, imipramine and fluoxetine by 
human brain microsomes. The deceased individuals and correspond- 
ing ages were: case I, 50 years (o); case II, 65 years (4) ;  case III, 16 
years ([2); case IV, 60 years (®); case V, 32 years (e); case VI, 60 
years (*) and case VII, 35 years (• ) .  The horizontal bar indicates 
the mean enzyme activity. The human brain regions are shown as 
cortex (CT), cerebellum (CE), midbrain (MB), medulla (MED), pons 
(PN), striatum (ST), hippocampus (HP) and thalamus (TH). 
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regions of brain did not reveal any significant differ- 
ences (Fig. 1A and B). 
The apparent kinetic constants K m and Vm~ x for 
FMO-mediated oxidation of various substrates by hu- 
man brain cortical microsomes (Case VI, see legend to 
Fig. 1A) are given in Table I. All the psychoactive 
drugs examined namely, chlorpromazine, imipramine 
and fluoxetine, exhibited high affinity (19.5, 22, 16 p,M, 
respectively) and high activity for the enzyme. The 
model substrate N,N-dimethylaniline exhibited bipha- 
sic kinetics namely, a high-affinity (1.2/xM), low activ- 
ity component and a low-affinity (2.3 mM), high activity 
component. Although the K m for methimazole was 
17.1 /zM, the Vma x was significantly lower than that 
observed for the psychoactive drugs (Table 1). 
'Western' immunoblot analyses of the microsomes 
from brain regions of two subjects (case VI and VII; 
see legend to Fig. 1A) using the antibody to purified 
rabbit pulmonary FMO revealed the presence of a 
single immunoreactive protein in all the regions of the 
brain that were examined (Fig. 2). Immunoblot experi- 
ments with antiserum to pig hepatic FMO did not 
reveal any cross-reactivity with the human brain FMO 
(data not shown). 
Immunocytochemical localization was carried out 
likewise using the above antibody. Among the brain 
regions (namely, cortex, cerebellum, midbrain and 
medulla) that were investigated for localization of 
FMO, significant immunolabelling was observed in the 
large reticular neurons of medulla oblongata (Fig. 3B), 
the substantia nigra (Fig. 3C) and the colliculi (Fig. 
3D). In the pons and medulla oblongata, the neurons 
of the V, VI, VII, IX and X cranial nerve nuclei and 
the pontine nuclei were stained. There was a variable 
degree of labelling of the neurons of the inferior oli- 
vary nucleus; the immunostaining extended further to 
the distant dendritic arborization (Figs. 3B and D). In 
the cerebellum, the large Purkinje cells and the small 
granule cells were stained. In the cerebral cortex, the 
staining was essentially restricted to the large pyrami- 
dal neurons of layer 5. Neuropil staining was also 
observed. The glia and the vascular elements were not 
stained and the fibre tracts showed variable intensity of 
staining (data not shown). 
The present study demonstrates the FMO-mediated 
metabolism of model substrates methimazole and 
N,N-dimethylaniline, and the psychoactive drugs 
imipramine, fluoxetine and chlorpromazine by human 
brain microsomes. Although the presence of FMO had 
been demonstrated in rat brain microsomes [2,3], to 
our knowledge the presence of this enzyme system had 
not been known in human brain. 
The distribution of FMO activity among the various 
regions of the brain that were examined id not reveal 
any striking differences (Fig. 1A and B). This is unlike 
that observed in the distribution of cytochrome P450 
and associated monooxygenase activities in the human 
brain wherein higher concentrations of that enzyme 
system were detected in the pons, medulla and mid- 
brain regions [14]. However, considerable inter individ- 
ual variations were detectable in the FMO activity 
from various human brain samples. The FMO-media- 
ted oxidation of N,N-dimethylaniline exhibited bipha- 
sic kinetics (Table 1), in a manner similar to that seen 
previously in rat brain [3]. A low-affinity, high-activity 
component of N,N-dimethylaniline oxidase activity was 
detectable when the substrate concentration was in the 
millimolar range, and a high-affinity, low-activity com- 
ponent was detectable when the substrate concentra- 
tion was in the micromolar ange. The oxidation of 
psychoactive drugs by human brain FMO exhibited 
both high affinity and high activity as compared with 
the model substrates (Table 1). 
FMO activity has been determined in human liver 
biopsy sample using N,N-dimethylaniline asa substrate 
[8]. The FMO activity in liver homogenate varied from 
1.06-1.96 nmol of N-oxide formed/min/mg protein. 
This is comparable to the high affinity component of 
FMO activity seen in brain microsomes (Fma x= 5.4 
nmol of NADPH ut i l ized/min/mg protein) using 
N,N-dimethylaniline assubstrate. Imipramine is metab- 
olized poorly by human liver FMO, while human kid- 
ney exhibits comparatively higher activity [10]. 
We observed that the human brain FMO mediated 
Fig. 2. 'Western' immunoblot fmicrosomes from human brain regions from two autopsy samples (A) case VI and (B) case VII, stained with 
antibody to purified rabbit pulmonary FMO. Each lane was loaded with 50 ~g of microsomal protein. The lanes were loaded as 1, cortex; 2, 
cerebellum; 3, midbrain; 4, medulla; 5, pons; 6, striatum; 7,hippocampus; and 8, thalamus. 
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imipramine N-oxidase activity var ied depending on the 
concentrat ion of microsomal protein present in the 
incubation medium. Thus, when the microsomal pro- 
tein concentrat ion was 5-15 /.Lg/ml incubation, the 
activity was 96.5 nmol /min /mg protein (Fig. 1). When 
the microsomal protein concentrat ion was increased to 
50 and 100 tzg of p ro te in /ml  incubation, the activity 
was observed to be 16.1 and 12.9 nmol of NADPH 
ox id i zed /min /mg prote in  respectively (data not 
shown). In an earl ier  study using human kidney micro- 
somes, the rate of imipramine N-oxidation was ob- 
served to be 1.22 nmol of imipramine N-oxide 
fo rmed/min /mg protein, using 700 ~g of microsomal 
p ro te in /ml  incubation. Thus, a direct comparison of 
the activities determined in the present study with 
those descr ibed in the earl ier  study [10] is difficult. 
The human brain FMO exhibited immunological  
similarity with rabbit pulmonary FMO as examined by 
'Western '  immunoblot.  Immunochemical  studies using 
the above antibody revealed the local ization of human 
brain FMO predominant ly  in the neuronal  cell bodies. 
Ear l ier  immunocytochemical  studies on the local ization 
of cytochrome P450 in human brain had also revealed 
the preferent ia l  localization of P450 in the neuronal  
cell soma [14]. It thus appears that both P450 and 
FMO are co-local ized in the brain. Thus, the in situ 
FMO-mediated  oxidative metabol ism of psychoactive 
drugs in brain probably takes place in neuronal  cells, 
some of which presumably are the site(s) of action of 
these agents. Since the N-oxides of these drugs may 
have different pharmacological  ctivities than the par- 
ent compounds,  the neuronal  metabol ism of these 
agents conceivably could modulate significantly their 
local pharmacological  effects. 
In conclusion, the present study demonstrates  the 
presence of FMO activity in diverse human brain re- 
gions and points to its potent ial  role in the local 
pharmacological  modulat ion of pharmacological  ctiv- 
ity and/or  toxicity of psychotropic drugs, and possibly 
other foreign compounds,  that are subject to FMO-  
mediated oxidative metabol ism. The considerable in- 
terindividual variations een in the distr ibution of FMO 
activity in human brain might help to explain the 
variable psychotropic drug responses een typically in a 
diverse pat ient populat ion.  
The authors thank Dr. D. M. Ziegler  and Dr. D. E. 
Wi l l iams for providing the ant ibodies to pig hepatic 
and rabbit pulmonary FMO.  We thank Sun Pharma- 
ceutical Industr ies and Torrent  Pharmaceut icals  Ltd. 
India for the gift of the psychoactive drugs used in this 
study. S.V.B. thanks CSIR,  India for the award of 
senior research fellowship. This work was supported 
through the US- India  fund for Cultural,  Educat ional  
and Scientific Co-operat ion.  
[1] Ayesh, R., AI-Waiz M. and Crother, N.J., Deficient nicotine 
N-oxidation in two sisters with trimethylaminuria, Br. J. Clin. 
Pharmacol., 25 (1988) 664-665. 
[2] Bhamre, S. and Ravindranath, V., Presence of flavin-containing 
monooxygenase in rat brain, Biochem. Pharmacol., 42 (1990) 
442-444. 
[3] Bhamre, S., Bhagwat, S.V., Shankar, S.K., Williams, D.E. and 
Ravindranath, V., Cerebral flavin-containing monooxygenase- 
mediated metabolism of antidepressants i  brain: immunochem- 
ical properties and immunohistochemical localization, J. Phar- 
macol. Exp. Then, 267 (1993) 555-559. 
[4] Bhamre, S., Shankar, S.K., Bhagwat, S.V. and Ravindranath, V., 
Catalytic activity and immunohistochemical localization of 
flavin-containing monooxygenase in rat kidney, Life Sci. 52 
(1993) 1601-1607. 
[5] Bradford, M.M., A rapid and sensitive method for the quantita- 
tion of microgram quantities of protein utilizig the principle of 
protein dye-binding, Anal, Biochem. 72 (1976) 248-254. 
[6] Cholerton, S. and Smith, R.L., Human pharmacogenetics of 
nitrogen oxidations. In P. Hlavic and L.A. Damani (Eds.), 
N-oxidation of Drugs: Biochemistry, Pharmacology, Toxicology, 
Chapman and Hall, London, 1991, pp. 107-131. 
[7] Dolphin, C., Shephard, E.A., Povey, S., Palmer, C.N., Ziegler, 
D.M., Ayesh, R., Smith, R.L. and Phillips, I.R., Cloning, pri- 
mary sequence and chromosomal mapping of a human flavin- 
containing monooxygenase (FMO1), J. Biol. Chem., 266 (1991) 
12379-12385. 
[8] Gold, M.S. and Ziegler, D.M., Dimethylaniline N-oxidase and 
aminopyrine N-demethylase activities of human liver tissues, 
Xenobiotica, 3(1973) 179-189. 
[9] Laemmli, U.K., Maturation of the head of bacteriophage T 4. 
DNA packaging events, Nature, 227 (1970) 680-685. 
[10] Lemoine, A, Johann, M. and Cresteil, T., Evidence of presence 
of distinct flavin-containing monooxygenases in human tissues, 
Arch. Biochem. Biophys., 276 (1990) 336-342. 
[11] Lomri, N., Gu, Q. and Cashman, J.R., Molecular cloning of the 
flavin-containing monooxygenases (form II) cDNA from adult 
human liver, Proc. Natl. Acad. Sci. USA, 89 (1992) 1685-1689. 
[12] Lowry, O.H., Rosenburg, N.J., Farr, A.L. and Randall, R.J., 
Protein measurement with the Folin phenol reagent, J. Biol. 
Chem., 193 (1951) 265-275. 
[13] Poulsen, L.L., Hyslop, R.M. and Ziegler, D.M., S-oxidation of 
thioureylenes catalyzed by a microsomal flavoprotein mixed 
function oxidase, Biochem. Pharmacol., 23 (1974) 3431-3440. 
[14] Ravindranath, V., Anandatheerthavarada, H.K. and Shankar, 
S.K., Xenobiotic metabolism in human brain-presence of cy- 
tochrome P450 and associated monooxygenases, Brain Res., 496 
(1989) 331-335. 
[15] Towbin, H., Staehelin, T. and Gordan, J., Electrophoretic rans- 
fer of proteins from polyacrylamide g ls to nitrocellulose sheets; 
procedure and some applications, Proc. Natl. Acad. Sci. USA, 76 
(1979) 4350-4354. 
[16] Tynes, R.E. and Philpot, R.M., Tissue and species dependent 
expression of multiple forms of mammalian flavin-containing 
monooxygenase, Mol. Pharmacol., 31 (1987) 569-574. 
[17] Williams, D.E., Halle, S.E. Muerhoff, A.S. and Masters, B.S.S., 
Rabbit lung flavin-containing monooxygenase: purification, 
characterization and induction during pregnancy, Mol. Pharma- 
col., 28 (1985) 381-391. 
[18] Ziegler, D.M., Recent studies on the structure and function of 
multisubstrate flavin-containing monooxygenases, Annu. Retd. 
Pharmacol. Toxicol., 33 (1993) 179-199. 
[19] Ziegler, D.M. and Poulsen, L.L., Hepatic microsomal mixed 
function oxidase. In S. Fleischer and L. Poulsen (Eds.), Methods 
in Enzymology, Vol. 52, Academic Press, New York. 1978, pp. 
142-151. 
